albumin-modified manganese-based nanoprobes

Albumin-modified manganese-based nanoprobes are a class of nanoparticle drug delivery and imaging agents composed of manganese ions or oxides stabilized or encapsulated by serum albumin (commonly bovine serum albumin). These nanosystems leverage the biocompatibility, non-immunogenicity, and tumor-targeting properties of albumin to deliver therapeutic or diagnostic payloads. The inclusion of manganese imparts additional functionalities such as magnetic resonance imaging (MRI) contrast enhancement and modulation of the tumor microenvironment. Mechanistically, these probes can activate immune responses via TLR4-dependent signaling in macrophages and serve as theranostic agents for cancer therapy by enabling both targeted drug delivery (including siRNA) and real-time MRI monitoring. They have demonstrated efficacy in preclinical models for enhancing tumor accumulation, improving oxygenation in hypoxic tumors, depleting glutathione to sensitize tumors to chemotherapy/chemodynamic therapy (CDT), reprogramming tumor-associated macrophages toward anti-tumor phenotypes, and inhibiting tumor growth[2][3][4].

Other names

albumin-stabilized manganese-based nanoparticlesMn@BSA nanocomplexesRGD-BMnNPsalbumin-manganese nanoprobes